At the end of the latest market close, Second Sight Medical Products Inc. (EYES) was valued at $2.10. In that particular session, Stock kicked-off at the price of $2.05 while reaching the peak value of $2.19 and lowest value recorded on the day was $2.02. The stock current value is $2.12.Recently in News on August 11, 2021, Second Sight Medical Products Announces a New NIH Grant Supplement for Its Orion Study. Grant proceeds support a patient preference information study of Orion subjects. You can read further details here
Second Sight Medical Products Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $20.00 on 03/09/21, with the lowest value was $1.40 for the same time period, recorded on 03/04/21.
3 Tiny Stocks Primed to Explode The world’s greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We’ve set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Second Sight Medical Products Inc. (EYES) full year performance was 143.06%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Second Sight Medical Products Inc. shares are logging -89.40% during the 52-week period from high price, and 157.22% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $0.82 and $20.00.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 804399 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Second Sight Medical Products Inc. (EYES) recorded performance in the market was 13.37%, having the revenues showcasing -42.55% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 83.53M, as it employees total of 12 workers.
Specialists analysis on Second Sight Medical Products Inc. (EYES)
During the last month, 0 analysts gave the Second Sight Medical Products Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 3.36, with a change in the price was noted -2.25. In a similar fashion, Second Sight Medical Products Inc. posted a movement of -51.49% for the period of last 100 days, recording 1,721,478 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for EYES is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Trends and Technical analysis: Second Sight Medical Products Inc. (EYES)
Raw Stochastic average of Second Sight Medical Products Inc. in the period of last 50 days is set at 7.47%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 8.33%. In the last 20 days, the company’s Stochastic %K was 5.82% and its Stochastic %D was recorded 4.27%.
Now, considering the stocks previous presentation, multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 13.37%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -58.75%, alongside a boost of 143.06% for the period of the last 12 months. The shares increased approximately by -17.83% in the 7-day charts and went up by -24.01% in the period of the last 30 days. Common stock shares were lifted by -42.55% during last recorded quarter.